We apologize your item could not be found. Not all items are listed on our website. Please contact your account manager for details regarding your searched item.
Material number (eg: xxxxxxxxxxx) no space or hyphen needed.
No Results Found
Most physicians agree - of all the services that can be performed for patients, eliminating the pain and fear of injections is at the top of the list. How can pain be minimized? One approach is to maximize syringe performance - whether the syringe is employed by a clinician, in an autoinjector, or in a wearable device. A critical element of syringe performance is the break-loose force. This is the force needed to overcome the plunger inertia in a filled syringe to initiate plunger movement and introduction of drug product. A lower, more consistent, break-loose force can provide for increased patient comfort.
Break-loose force can be influenced by several factors: plunger design, elastomer formula, coatings on plunger and syringe, materials and needle gauge. West considers these factors in designing products, in particular:
NovaPure® is a registered trademark of West Pharmaceutical Services, Inc., in the United States and other jurisdictions.
Daikyo Crystal Zenith® is a registered trademark of Daikyo Seiko, Ltd.
Daikyo Crystal Zenith® technology is licensed from Daikyo Seiko, Ltd.
Several of West’s experts will be featured speakers at The Universe of Prefilled Syringes and Injection Devices organized by 2013 PDA Europe, which will be held November 5-6, 2013, in Basel, Switzerland. West’s representatives will report on the latest trends in the world of prefilled syringes and innovations in the field of self-injection devices.
West is proud to participate in Pharmapack’s upcoming symposium focused on Primary Packaging and Drug Delivery Trends for Injectables. The meeting, that will include presentations from leading suppliers and partners to the pharmaceutical industry, will be held on <strong>April 23</strong> in <strong>New York</strong> at the <strong>W- Times Square</strong>.
Our One West team is a diverse population from around the globe with different life, educational and cultural experiences. These differences are valued and make West a place where innovation and growth is continuously occurring to help achieve the demands of the industries we serve. Our team comes together, bringing their own unique perspectives and shared vision of a healthier world.
<em>Summary of FDA’s recent Inspection for visible particles draft guidance “Inspection of Injectable Products for Visible Particulates” and how it applies to components</em><br />The visual inspection of injectable drug product has been a regulatory requirement since 1936<sup>1</sup>, however, successful implementation of the standard has been challenging for many organizations. The number of recall notices issued by the U.S. Food and Drug Administration (FDA) from 2010 through 2019 for injectable products due to visible particulate have reduced since 2014 but at the current trend, will be some time before it approaches zero<sup>2</sup>. Between 2009 and 2019, the presence of visible particles in parenteral product was the second leading cause for product recalls.<sup>3</sup> Patient safety is the main driver for requiring injectable products to meet the criteria of “essentially free of visible particulates.”<sup>4</sup>
Information is a powerful tool and West&rsquo;s Knowledge Center has been updated to provide our customers with an improved user experience. We&rsquo;ve completed a comprehensive overhaul of the Knowledge Center user interface, including a filter-based search design, more modern look and feel, and easy access to trending articles, new content, and FAQ&rsquo;s answered by West Subject Matter Experts.
English
Chinese
